0Y71 Malin Corporation Plc

TIDM0Y71

RNS Number : 7366J

Malin Corporation PLC

28 April 2022

Malin Corporation plc

Viamet's Successor Company, Mycovia, announces FDA approval of VIVJOA(TM) (otesecanazole) for the treatment of recurrent vulvovaginal candidiasis

-- VIVJOA(TM) is the first and only FDA approved medication for the treatment of recurrent vulvovaginal candidiasis (RVVC) (Chronic Yeast Infection)

   --    Mycovia expects to commercially launch the drug in the United States during Q2 2022. 

Dublin-Ireland, 28 April 2022 : Malin Corporation plc. (Euronext Growth Dublin:MLC) (Malin), a company investing in highly innovative life sciences companies, is pleased to note that Mycovia, the successor company to Malin's investee company Viamet, has announced the approval from the United States Food and Drug Administration (FDA) of VIVJOA(TM) (otesecanazole) for the treatment of RVVC in females with a history of RVVC and who are not of reproductive potential.

Mycovia is planning its commercial launch of VIVJOA(TM) in the second quarter of 2022.

"The approval of VIVJOA(TM) in the US is a significant milestone and is based on the excellent efficacy and safety data reported by Mycovia from its three Phase 3 trials of otesecanazole including 875 patients across 11 countries," said Darragh Lyons, Malin Chief Executive Officer. "The approval will result in the initiation of recurring cash inflows from milestone payments and royalties to Malin as a Viamet shareholder before the end of 2022."

Malin owns approximately 15% of Viamet.

A copy of Mycovia's press release is available to view at the following link:

http://www.rns-pdf.londonstockexchange.com/rns/7366J_1-2022-4-28.pdf

This announcement contains inside information for the purposes of the Market Abuse Regulation (EU) No 596/2014 (MAR).

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com

For further information please contact:

Malin

Fiona Dunlevy, Company Secretary

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

Liberum (Joint Broker)

Phil Walker / Ben Cryer

Tel: +44 (0) 20 3100 2000

Powerscourt (Media enquiries)

Eavan Gannon

Tel: +353 87 236 5973

malin@powerscourt-group.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFSLSLITFIF

(END) Dow Jones Newswires

April 28, 2022 08:05 ET (12:05 GMT)

Malin (LSE:0Y71)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Malin (LSE:0Y71)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025